Received: Added at production | Revised: Added at production | Accepted: Added at production

DOI: xxx/xxxx

ORIGINAL ARTICLE

High orientation and low delayed recall in the standardisation of the Spanish version of the Montreal Cognitive Assessment (MoCA) in elders of Peru

Lucia Bulgarelli[1] | **Emilia Gyr**[2] | **Jose Villanueva**[2] | **Koni Mejía**[3] | **Claudia Mejía**[3] | **Renato Paredes**[2] | **Sheyla Blumen**[2]

[1]Independent Researcher, Lima, Peru

[2]Department of Psychology, Pontifical Catholic University of Peru, Lima, Peru

[3]EDMECON, Lima, Peru

Correspondence
Renato Paredes
Email: renato.paredes@pucp.edu.pe

Present address
Av. Universitaria 1801, San Miguel, 15088, Lima, Perú.

Abstract

INTRODUCTION: The elderly in Peru face healthcare barriers in detecting cognitive impairment and dementia due to a lack of validated tools. The Montreal Cognitive Assessment (MoCA) effectively detects early dementia, assessing visuo-spatial function, executive function, naming, memory, attention, language, abstraction, and orientation.

METHODS: This study aims to standardise the Spanish version of the MoCA for the elderly in Lima. The test was administered to 338 elders from three institutions: Municipality of San Miguel District, San José Obrero Polyclinic, and EDMECON. Regression-based normed scores were computed, adjusted for age and education.

RESULTS: Our results show high orientation scores and low delayed recall, highlighting cognitive strengths and weaknesses in our sample. Age and education significantly influenced cognitive performance, with education as the strongest predictor.

DISCUSSION: This study offers normative data for the Peruvian elderly, aiding the clinical use of MoCA in Peru. We discuss appropriate cut-off points and cultural sensitivity in the Peruvian context.

KEYWORDS

MoCA, dementia, cognitive decline, elderly, neuropsychology

1 | INTRODUCTION

Dementia represents a set of pathologies whose common characteristic is the death of neuronal cells, triggering a degenerative and irreversible process affecting the nervous system[1,2]. Dementia is a clinical syndrome that involves irreversible loss of cognitive functions, especially memory, significantly compromising daily activities[3]. Diagnosis requires a substantial decrease in patient autonomy and quality of life compared to a premorbid stage, not attributable to other medical or psychiatric causes[4]. Neurocognitive disorders are among the most prevalent age-related disorders worldwide and lead to substantial morbidity and mortality[5–7].

The prevalence of dementia among individuals aged 60 years and older is approximately 8.5% in Latin America[8] with projections indicating an increase from 7.8 million in 2013 to 27 million by 2050[9,10]. The Global Burden of Disease (GBD) study shows that neurodegenerative diseases in Peru, measured in Disability Adjusted Life Years (DALY), rose from the fifth to the third largest contributor to neurological diseases[11]. A recent study in Peru[12,13] found a 6.85% prevalence of dementia in 1,532 individuals over 65 in Lima, with Alzheimer's disease (AD) as the predominant diagnosis. Plausible factors contributing to these findings include the ageing of the population, poor access to health services, low diagnostic capacity of dementia in primary care services, and limited recognition of symptoms by family members and caregivers[13]. Given the recent increase in life expectancy, it is plausible that AD incidence will rise, potentially tripling by 2050[4,14].

Abbreviations: MoCA: Montreal Cognitive Assessment.

 © 2023 Copyright Holder Name

There is no cure for dementia, only drugs to slow its progression[15]. For this reason, early diagnosis is beneficial for patients and their caregivers and can result in substantial cost savings for healthcare systems[16]. In fact, early diagnosis provides numerous benefits to the patient: (a) greater and more effective adherence to pharmacological and rehabilitative treatments, (b) the possibility of participating in treatments that are still experimental, and (3) the possibility of organising one's life in relation to the progression of the disease[17].

Diagnosing dementia in Latin America faces critical issues: tests are rarely performed in primary care. This leads to a high number of cases of dementia that go unnoticed and misdiagnosed[18]. In this context healthcare workers can identify dementia with a 66% positive predictive value after a few hours of training[18].

Several cognitive screening tools for MCI and dementia[19,20] have low sensitivity for early detection[21]. Most tests are complex, needing trained personnel and specialised equipment[22], often unavailable in primary care. Consequently, MCI is frequently unrecognised in primary care[22].

Promoting research on short cognitive tests validated for Peru[23] is essential, similar to neuropsychological test validation projects in other countries (for example, the NEURONORMA projects in Spain[24] and Colombia[25]). To date, several short cognitive tests have been validated in the context of Lima (Peru), including the Clock Drawing Test (CDT)[26 27]; the Addenbrooke's Cognitive Examination (ACE)[28]; the INECO frontal screening test (IFS)[29] and the memory impairment test (M@T)[30,31]. However, the MoCA test ("https://mocacognition.com/") has not been validated in the Peruvian context.

MoCA is presented as a brief, reliable, and valid test for neurocognitive evaluation given its high degree of sensitivity and specificity for MCI and dementia[22,32]. Currently, the MoCA is available in multiple translated versions, including adaptations for individuals with visual impairments, as well as video and telephone formats. These adaptations improve the accessibility and usability of the test, particularly in longitudinal studies, by minimising sample bias and mitigating participant attrition[33]. Thus, it arises as a promising alternative for the detection of early cognitive impairment by general practitioners[34]. In the Latin America region, there is a tendency to use the original Spanish version of the MoCA test due to the scarcity of studies related to its validity and cross-cultural adaptation. This situation may result in practices that are not in compliance with international diagnostic standards[35]. The objective of this study is to standardise the Spanish version of the Montreal Cognitive Assessment Test (MoCA) for the elderly in Lima-Peru, assessing the impact of age, sex, and educational level. In addition, the norms for the Lima elderly population will be developed taking into account age and educational level.

2 | METHODS

2.1 | Participants

Participants were recruited from three institutions within the Metropolitan Lima: the EDMECON medical centre, the San José Obrero Polyclinic, and the San Miguel Municipality. The sample consisted of 338 seniors over 60 years of age (122 male, 216 female), including both native Spanish speakers and those who spoke Spanish as a second language (with proficiency exceeding 10 years). Sociodemographic data, including variables such as sex, age, date of birth, years of education, and medical diagnoses, were systematically collected (Table 1). The age was divided into six ranges: 60-64, 65-69, 70-74, 75-79, and 80+ years after the research conducted by the National Institute of Informatics and Statistics (INEI) of Peru[36]. Similarly, years of education were divided into three ranges: 0-6, 7-11 and 12 + years following the education levels reported by INEI[37]: Primary, Secondary, and Higher.

TABLE 1 Sociodemographic characteristics of the sample.

		Male (n=122)		Female (n =216)		Total(n=338)		
		n	%	n	%	n	%	X^2(p)
Age group	60 - 64 years	11	9.0	40	18.5	51	15.0	
	65 - 69 years	26	21.3	44	20.3	70	20.7	
	70 - 74 years	24	19.6	49	22.6	73	21.5	8.0(0.08)
	75 - 79 years	22	18.0	35	16.2	57	16.8	
	>80 years	39	31.9	48	22.2	87	25.7	
Educational level	Primary (0 - 6 years)	19	15.5	50	23.1	69	20.4	
	Secondary (7 - 11 years)	51	41.8	90	41.6	141	41.7	3.3(0.18)
	Higher (>12 years)	52	42.6	76	35.1	128	37.8	

Individuals with auditory or visual impairments, psychiatric diagnoses, concurrent cerebrovascular pathologies, intellectual disability, traumatic brain injuries, and substance abuse disorders were excluded from the sample.

2.2 | Instrument

Montreal Cognitive Assessment (MoCA) is a validated cognitive screening tool renowned for its efficacy in the early detection of dementia[38]. The administration of the test typically takes around 10 minutes. The test evaluates eight key cognitive domains: visuospatial and executive function, naming, memory, attention, language, abstraction, and orientation (see Table 2). The original MoCA scoring system incorporates a correction factor, adding one point to the total score for individuals with fewer than 12 years of education (28). Here, we aim at estimating the adjustments due to age and education for our population.

TABLE 2 MoCA Item Distribution and Assigned Scores.

Cognitive domain	Subtest	Task	Maximum score
Visuospatial Skills / Executive Functions	Shortened TMT-B	It is evaluated using a graphic alternation task adapted from the Trail Making Test B.	1
	Cube Copying	It is evaluated with the copy of a geometric cube.	1
	Clock Drawing Test	It is evaluated using the copy of the clock test.	3
Naming	Identifying Animal Figures (Lion, Rhino, Camel)	It is evaluated using three items, naming by visual confrontation of three animals with a low degree of familiarity.	3
Attention	Dígits	Direct reverse digits	1
	Inverse dígits	Reverse digits	1
	Tapping Test - letter A	Sustained attention	1
	Subtraction of 7 from 100	A series of subtractions	3
Lenguage	Phrase Repetition	Repetition of two complex sentences	2
	Word Fluency	Phonetic fluency (number of words that begin with the letter F during one minute)	1
Abstraction	Similarities	It is made up of two abstract verbal reasoning items	2
Memory	Delayed Recall	It consists of two learning trials of five words (they do not score) for which questions are asked in a deferred manner after five minutes.	5
Orientation	Day of the Month (Date)	Temporal and spatial orientation is evaluated.	1
	Month		1
	Year		1
	Day of the week		1
	Place		1
	Location		1

2.3 | Procedure

Contact with participants was conducted within the context of a medical appointment at the three institutions. In the case of the Private Centre Medical EDMECON and the National Polyclinic of San José Obrero, the evaluation was performed as part of the patient's medical evaluation, and authorisation was requested to obtain the data by informed consent. In the case of the Municipality, the data collection was parallel to the outpatient medical care provided by the institution, where elderly were visited at their homes.

2.4 | Data Analysis

We examined the potential effects of age, years of education, and sex in the raw scores of MoCA for the total sample. We evaluated sex differences in the total score and each of the cognitive domains of the MoCA using the Mann-Whitney U tests. We used the Bonferroni[39] correction of p-values to control for the family-wise error rate of multiple comparisons.

We explored associations of age and years of education with the total score and each of the cognitive domains of the MoCA using the Kendall correlation coefficient (τ_b) and the determination coefficient (r^2). Here, we employed the Bonferroni correction to control for the family-wise error rate for each test. Potential differences in cognitive performance according to age group and educational level were analysed using the Kruskal-Wallis H test and Bonferroni corrected post hoc Dunn tests[40].

Finally, we computed regression-based normed scores of the total MoCA scores adjusted for age and years of education following the procedure described in the NEURONORMA project[24,41]. First, raw scores were converted to percentile ranks (Pc). These ranks were rescaled to a truncated normal distribution (M: 10, SD: 3) bounded between 2 and 18 to generate Scaled Scores adjusted for age (SS_a). This procedure was used for the entire sample and each age group.

Next, adjustments for years of education were modelled using a linear regression:

$$SS_a = \alpha + \beta * EducYears + \epsilon$$

The estimated regression coefficient (β) here was employed to calculate Scaled Scores adjusted for age and years of education (SS_{ae})[42]:

$$SS_{ae} = SS_a - \beta * (EducYears - 11)$$

We selected a cut-off point of 11 years of education because it represents the period of basic education (Primary and Secondary) in Peru.

Data preprocessing, visualisations and statistical analyses were performed with Pandas[43], Seaborn[44] and Pingouin[45] software libraries of the Python programming language.

3 | RESULTS

The sociodemographic characteristics of the 338 participants in terms of age, education level, and sex are shown in Table 2. The mean cognitive performance of the total sample was 18.2 ± 5.6 for the total MoCA score. The scaled scores for each subtest are shown in Figure 1.



FIGURE 1 Scaled scores of MoCA subtests.

3.1 | Effects of sex, age and education

We did not find significant differences in the total scores of MoCA grouped by sex. However, we observed that men scored higher on identification (U = 10984.5, $p = .023$) and attention (U = 10540.5, $p = .015$) than women. No significant differences were found for other cognitive domains (see Table 3).

The results of the correlation analysis for age and years of education are shown in Table 4. Both age and years of education were significantly correlated with the MoCA total score and its subtests. We found that age was a significant negative predictor of the total MoCA score and its subtests. In contrast, we found that years of education were a significant positive predictor of the total score of MoCA and its subtests. Age and years of education explain 12.17% and 24.67% of the total scores of MoCA, respectively.

We found a significant main effect of the age group on the total MoCA scores (H = 40, $p < .001$). Post hoc pairwise comparisons revealed significant differences between the 80 + (Me = 15, IQR = 7) group and the 60-64 (Me = 22, IQR = 6.5) ($p < .001$), 65-69 (Me = 21, IQR = 8.75) ($p < .001$) and 70-74 (Me = 19, IQR = 6) ($p = .004$) groups. Similarly, significant differences were found between the 60-64 group and the 75-79 (Me = 19, IQR = 10) group ($p = .031$).

Similarly, we found a significant main effect of the educational level on the total scores of MoCA (H = 79.80, $p < .001$). Post hoc pairwise comparisons revealed significant differences between the Primary education group (Me = 13, IQR = 6) and the Secondary (Me = 19, IQR = 5) ($p < .001$) and the Higher Education groups (Me = 22, IQR = 7) ($p < .001$). Furthermore, significant differences were found between the Secondary and Higher Education groups ($p < .001$).

TABLE 3 MoCA scores grouped by sex.

Sex	MoCA Visosp/Exec	MoCA Identification	MoCA Attention	MoCA Language	MoCA Abstraction	MoCA Delayed recall	MoCA Orientation	MoCA Total
Male (n=122)								
Median	3.0	3.0	4.0	2.0	1.0	1.0	6.0	19.0
IQR	2.0	1.0	2.0	1.0	2.0	3.0	0.75	6.0
Female (n=216)								
Median	2.0	3.0	4.0	1.0	1.0	1.0	6.0	18.0
IQR	3.0	1.0	3.0	1.0	2.0	3.0	1.0	8.25
Total (n=338)								
Median	3.0	3.0	4.0	1.0	1.0	1.0	6.0	19.0
IQR	3.0	1.0	2.0	1.0	2.0	3.0	1.0	8.0

TABLE 4 Correlation analysis between the Montreal Cognitive Assessment (MoCA) and the demographic variables of age and years of education

	Age		Years of Education	
	τ_b	r^2	τ_b	r^2
Visospatial/Executive	-0.22*	0.09*	0.34*	0.16*
Identification	-0.17*	0.04*	0.19*	0.06*
Attention	-0.15*	0.04*	0.27*	0.12*
Language	-0.16*	0.04*	0.34*	0.17*
Abstraction	-0.19*	0.06*	0.31*	0.13*
Delayed recall	-0.17*	0.05*	0.18*	0.05*
Orientation	-0.20*	0.05*	0.27*	0.11*
MoCA Total	-0.24*	0.12*	0.37*	0.24*

*p <0.05

3.2 | Age and education adjusted norms

Age-adjusted scale scores obtained from our sample are presented in Table 5. Total scores, percentile values (Pc), age-adjusted scaled scores (SS_a), and scores for the total sample and the five age groups are presented. Following[42], we suggest cutoff scores to classify cognitive performance in the test based on the following criteria:

- Obtaining a scaled score of 10 or more and a Pc of 44-56 (or more) would not be considered impairment.
- Obtaining a scaled score of 7 (one standard deviation below the mean) and a Pc of 13-43 would correspond to mild cognitive impairment.
- Obtaining a scaled score of 4 (two standard deviations below the mean) and a Pc of 2-12 would correspond to moderate cognitive impairment.
- Obtaining a scaled score of 2 (three standard deviations below the mean) and a Pc < 1 would correspond to severe cognitive impairment.

For the total sample, cognitive performance is considered normal or non-impaired when a score of ≥ 17 is obtained.

Years of education significantly predicted SS_a ($r^2 = .239$, $p < .001$) with a coefficient of 0.347. Following[24], we used this coefficient to calculate age and education adjusted scaled scores (SS_{ae}) for each combination of SS_a and years of education observed in the sample. We present SS_{ae} in Table 6.

4 | DISCUSSION

The purpose of this study was to standardise the Spanish version of the Montreal Cognitive Assessment (MoCA) for the elderly population in Lima. Standardising this test in Peru is crucial for an accurate cognitive evaluation, considering the high prevalence of neurocognitive disorders[8,13] and the lack of cognitive tools adapted to the sociodemographic and cultural context of the country. Furthermore, early detection of cognitive disorders such as dementia improves patient prognosis, quality of life, and reduces economic and social burdens[3], which is critical for developing countries.

We examined the effect of sex, age, and education on MoCA scores. In line with previous research using MoCA[24,42], we found significant effects on overall cognitive performance of age and education, but not for sex. In addition, we found that education predicts cognitive performance better than age.

TABLE 5 Scaled scores and percentiles for each age group.

		Suggested cutoff score	Total Montreal Cognitive Assessment raw scores					
SS_a	Pc	Cognitive Impairment	Total sample	60 - 64	65 - 69	70 - 74	75 - 79	80 +
2	<1	Severe	3	-	-	-	-	-
3	1		4 - 6	-	9	6	3	4
4	2-3	Moderate	7	10 - 11	11	7	-	5
5	4-6		8 -9	13	13	8 - 10	7	6 - 7
6	7-12		10 - 12	14	14	11 - 12	8	8 - 10
7	13-20	Mild	13 - 14	15 - 17	15	14 - 15	9 - 11	11 - 12
8	21-30		15 - 16	18 - 20	16 - 17	16 - 17	12 - 15	13
9	31-43		17 - 18	21	18 - 20	18	16 - 18	14 - 15
10	44-56	Non impaired	19 - 20	22	21 - 22	19 - 20	19 - 20	16 - 17
11	57-68		21 - 22	23	23 - 24	21 - 22	21 - 22	18
12	60-79		23	24	25	23	23	19 - 20
13	80-86		24 - 25	25	26	24	24	21 - 22
14	87-92		26 - 27	26	27	26 - 27	25	23
15	93-95		28	27	28	28	-	26
16	96-97		29	28	29	-	29	27
17	98		-	-	-	-	-	-
18	>99		-	29	-	29	-	28

Pc: Percentile; SS_a: Age-adjusted scaled score.

TABLE 6 Scales scores adjusted for age and years of education.

		Years of education																				
SS_a	Pc	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
2	<1	5.0	5.0	5.0	4.0	4.0	4.0	3.0	3.0	3.0	2.0	2.0	2.0	1.0	1.0	0.0	0.0	0.0	-1.0	-1.0	-1.0	-2.0
3	1	6.0	6.0	6.0	5.0	5.0	5.0	4.0	4.0	4.0	3.0	3.0	3.0	2.0	2.0	1.0	1.0	1.0	0.0	0.0	0.0	-1.0
4	2-3	7.0	7.0	7.0	6.0	6.0	6.0	5.0	5.0	5.0	4.0	4.0	4.0	3.0	3.0	2.0	2.0	2.0	1.0	1.0	1.0	0.0
5	4-6	8.0	8.0	8.0	7.0	7.0	7.0	6.0	6.0	6.0	5.0	5.0	5.0	4.0	4.0	3.0	3.0	3.0	2.0	2.0	2.0	1.0
6	7-12	9.0	9.0	9.0	8.0	8.0	8.0	7.0	7.0	7.0	6.0	6.0	6.0	5.0	5.0	4.0	4.0	4.0	3.0	3.0	3.0	2.0
7	13-20	10.0	10.0	10.0	9.0	9.0	9.0	8.0	8.0	8.0	7.0	7.0	7.0	6.0	6.0	5.0	5.0	5.0	4.0	4.0	4.0	3.0
8	21-30	11.0	11.0	11.0	10.0	10.0	10.0	9.0	9.0	9.0	8.0	8.0	8.0	7.0	7.0	6.0	6.0	6.0	5.0	5.0	5.0	4.0
9	31-43	12.0	12.0	12.0	11.0	11.0	11.0	10.0	10.0	10.0	9.0	9.0	9.0	8.0	8.0	7.0	7.0	7.0	6.0	6.0	6.0	5.0
10	44-56	13.0	13.0	13.0	12.0	12.0	12.0	11.0	11.0	11.0	10.0	10.0	10.0	9.0	9.0	8.0	8.0	8.0	7.0	7.0	7.0	6.0
11	57-68	14.0	14.0	14.0	13.0	13.0	13.0	12.0	12.0	12.0	11.0	11.0	11.0	10.0	10.0	9.0	9.0	9.0	8.0	8.0	8.0	7.0
12	60-79	15.0	15.0	15.0	14.0	14.0	14.0	13.0	13.0	13.0	12.0	12.0	12.0	11.0	11.0	10.0	10.0	10.0	9.0	9.0	9.0	8.0
13	80-86	16.0	16.0	16.0	15.0	15.0	15.0	14.0	14.0	14.0	13.0	13.0	13.0	12.0	12.0	11.0	11.0	11.0	10.0	10.0	10.0	9.0
14	87-92	17.0	17.0	17.0	16.0	16.0	16.0	15.0	15.0	15.0	14.0	14.0	14.0	13.0	13.0	12.0	12.0	12.0	11.0	11.0	11.0	10.0
15	93-95	18.0	18.0	18.0	17.0	17.0	17.0	16.0	16.0	16.0	15.0	15.0	15.0	14.0	14.0	13.0	13.0	13.0	12.0	12.0	12.0	11.0
16	96-97	19.0	19.0	19.0	18.0	18.0	18.0	17.0	17.0	17.0	16.0	16.0	16.0	15.0	15.0	14.0	14.0	14.0	13.0	13.0	13.0	12.0
17	98	20.0	20.0	20.0	19.0	19.0	19.0	18.0	18.0	18.0	17.0	17.0	17.0	16.0	16.0	15.0	15.0	15.0	14.0	14.0	14.0	13.0
18	>99	21.0	21.0	21.0	20.0	20.0	20.0	19.0	19.0	19.0	18.0	18.0	18.0	17.0	17.0	16.0	16.0	16.0	15.0	15.0	15.0	14.0

Pc: Percentile; SS_a: Age-adjusted scaled score.

Ageing leads to functional and structural brain deterioration, associated with cognitive decline and vulnerability to diseases such as dementia[46]. Research in biological ageing has identified markers that recognise differences between individuals in their ageing rate and risk of cognitive decline[47,48]. A meta-analysis revealed consistent evidence of declines in cognitive abilities such as memory, processing speed, and executive function with age[49]. Furthermore, there is evidence of an indirect association of accuracy in working memory tasks and ageing[50]. Our results align with the literature: MoCA performance decreases as age increases. However, many measures of biological age rely on associations with chronological age, which may not always be accurate[51].

Our observed effect of education on cognitive performance is consistent with the cognitive reserve theory[52,53]. This view suggests that the educational level and other forms of cognitive stimulation can help offset the effects of ageing and brain pathology. A recent analysis of global longitudinal studies of cognitive ageing supports this theory by showing that education reduces the risk of the characteristic cognitive decline observed in dementia[54]. Possibly, the development of cognitive skills due to formal education such as abstract reasoning, problem solving, language, and numerical literacy affects the observed performance on the MoCA. These results raise concerns related to the multiple challenges that living below the poverty line can create, such as malnutrition, that significantly affect educational achievement in Peru[55].

We only found sex differences in identification and attention, with men scoring higher than women. Current evidence supports sex differences in specific cognitive tasks, but not in overall cognitive performance: men generally perform better in mental rotation and visual–spatial working memory, while women show advantages in verbal and location memory[56]. Similarly, there is evidence suggesting a faster decline in global cognition and executive function in women due to ageing[57]. Our results may be compatible with this empirical evidence, showing that women score lower

than men in identification and attention, possibly due to faster cognitive decline. However, our sample had an unequal sex distribution and the observed sex differences may be influenced by the cultural context[58].

We provide normative data and suggested cut-off scores for the MoCA adapted to the Peruvian population, fostering its clinical use and interpretation in the country. This pioneering study is the first to standardise the MoCA test in Peru, enriching its scientific landscape, and expanding its impact to other Spanish-speaking countries by setting a new benchmark for future studies focused on the cognitive decline of seniors[24,42,59].

One of the most notable findings of our study was the notably low score on the delayed recall test (semantic memory) and the high score on the (spatiotemporal) orientation test. The observed memory scores could be attributed to sample-specific impairments in the encoding, storage, and retrieval processes, or changes in the interaction between encoding and retrieval[60,61]. In general, low delayed recall scores are associated with amnestic MCI[62] and may have negative implications on the daily activities of the evaluated individuals.

The exceptional performance in the orientation assessment indicates increased temporal and spatial acuity in our sample. This suggests preserved cognitive faculties and autonomy, relevant for excluding dementia diagnosis[63], as its loss indicates severe cognitive impairment in late-stage disease[64]. The observed high orientation scores may be the result of cognitive reserve accumulated by work activity[65]: Peruvians work more years on average than people in other countries and mainly under informal conditions[66]. Thus, good orientation skills help maintain workplace competitiveness and secure basic economic subsistence. Future studies could explore the significance and social impacts of these findings.

To our knowledge, this study is the first post-pandemic standardisation of the test. This may explain the remarkably low scores observed in our sample compared to previous MoCA standardizations in Spanish-speaking countries[42,59]. COVID-19 is thought to have direct impacts on cognitive functioning[67,68]. Empirical evidence suggests that this viral infection produces changes in the orbitofrontal cortex and parahippocampal gyrus (decrease in gray matter), in the primary olfactory cortex (changes in markers of tissue damage) and a reduction in the overall size of the brain[67]. Moreover, the implementation of social distancing protocols has had a profound impact on cognitive and physical activities, as well as social interactions. This disruption may have exacerbated levels of anxiety, depression, and stress responses[69,70], and has been associated with impairments in information processing speed and executive functions[71].

Hence, the results of our study are not directly comparable to any study carried out before the pandemic. We stress the need to update the original test standardisation to fit post-pandemic population characteristics. Adaptation to a post-pandemic environment may require adjustments to cognitive assessment expectations and methodologies. Such comprehensive revisions are critical to maintaining the relevance and accuracy of cognitive evaluations in this new era.

The study has limitations that must be taken into account when interpreting its results. Efforts to recruit a representative sample may still have under-represented certain demographics, affecting the external validity. Lack of long-term follow-up also limits the evaluation of the stability of the cognitive score and the prediction of future neurocognitive disorders. Another limitation is the lack of comparison with other cognitive evaluation tools and the absence of participants with a proper neuropsychological evaluation that confirms cognitive health. This affects the concurrent validity and sensitivity of the adapted MoCA compared to other instruments already available, limiting its use in the Peruvian context. Despite these limitations, the study represents an important step toward improving cognitive assessment in the elderly Peruvian population and highlights the need for more research in this field to address the cognitive health needs of the population in Latin America.

AUTHOR CONTRIBUTIONS

LB: Conceptualisation, Methodology, Investigation, Writing - Original Draft. EG: Conceptualisation, Methodology, Investigation, Writing - Original Draft. JV: Investigation, Writing - Original Draft. KM: Investigation, Writing - Reviewing and Editing. CM: Investigation, Writing - Reviewing and Editing. RP: Conceptualisation, Methodology, Software, Formal Analysis, Writing - Original Draft. SB: Supervision, Writing - Reviewing and Editing.

ACKNOWLEDGMENTS

We acknowledge the research group Creativity, Technology and Talent (CREA TALENTUM), the Computational Cognitive Neuroscience Lab, and the Academic Direction of Social Responsibility (DARS) of the Pontifical Catholic University of Peru, for providing the resources required for this project. We also thank San José Obrero Polyclinic, San Miguel District Municipality and EDMECON, for facilitating access to participants. We thank Tiffany Sandoval for her support in the data collection process.

FINANCIAL DISCLOSURE

None reported.

ETHICAL STATEMENT

The ethical approval for the study was granted by the Ethics Committee for Research in Social Sciences, Humanities and Arts of the Pontifical Catholic University of Peru under approval number 145-2023-CEI-CCSSHHyAA. Participation in the study was voluntary and all participants gave their informed consent indicating their understanding of the objectives of the study and their willingness to participate.

DATA SHARING AND DATA ACCESSIBILITY

The anonymised data sets and scripts employed for the analyses presented in this manuscript are accessible in the following public repository: https://github.com/neuropucp/MoCA-Peru

REFERENCES

1. Dugger BN, Dickson DW. Pathology of neurodegenerative diseases. Cold Spring Harbor perspectives in biology. 2017;9(7):a028035.
2. Abubakar MB, Sanusi KO, Ugusman A, Mohamed W, Kamal H, Ibrahim NH, et al. Alzheimer's disease: an update and insights into pathophysiology. Frontiers in aging neuroscience. 2022;14:742408.
3. Atri A. The Alzheimer's disease clinical spectrum: diagnosis and management. Medical Clinics. 2019;103(2):263–293.
4. Reitz C, Mayeux R. Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochemical pharmacology. 2014;88(4):640–651.
5. Sachdev PS, Blacker D, Blazer DG, Ganguli M, Jeste DV, Paulsen JS, et al. Classifying neurocognitive disorders: the DSM-5 approach. Nature Reviews Neurology. 2014;10(11):634–642.
6. Prince M, Ali GC, Guerchet M, Prina AM, Albanese E, Wu YT. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimer's research & therapy. 2016;8:1–13.
7. Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, et al. Defeating Alzheimer's disease and other dementias: a priority for European science and society. The Lancet Neurology. 2016;15(5):455–532.
8. Custodio N, Wheelock A, Thumala D, Slachevsky A. Dementia in Latin America: epidemiological evidence and implications for public policy. Frontiers in aging neuroscience. 2017;9:221.
9. Baez S, Ibáñez A. Dementia in Latin America: an emergent silent tsunami. Frontiers in aging neuroscience. 2016;8:253.
10. Chavez K, Alva-Diaz C, Reynoso-Guzman W, Cuenca MPCJ, Gamboa C, Lanata S. Objectives: To establish the diagnostic accuracy of the RUDAS-PE compared to expert clinical diagnosis using the Clinical Dementia Rating (CDR) Scale in healthy and cognitively impaired illiterate persons living in two culturally and geographically distinct rural communities of Peru. Dementia in Low and Middle Income Countries. 2022;.
11. Almubaslat F, Sanchez-Boluarte SS, Diaz MM. A review of neurological health disparities in Peru. Frontiers in Public Health. 2023;11:1210238.
12. Custodio N, García A, Montesinos R, Escobar J, Bendezú L. Dementia prevalence in a Lima, Peru urban community: door-to-door study. In: Anales de la Facultad de Medicina. vol. 69. UNMSM. Facultad de Medicina; 2008. p. 233–238.
13. Alva-Díaz C, Huerta-Rosario A, Pacheco-Barrios K, Molina RA, Navarro-Flores A, Aguirre-Quispe W, et al. Neurological diseases in Peru: a systematic analysis of the global burden disease study. Arquivos de Neuro-Psiquiatria. 2020;78:282–289.
14. Lane CA, Hardy J, Schott JM. Alzheimer's disease. European journal of neurology. 2018;25(1):59–70.
15. Singhal AK, Naithani V, Bangar OP. Medicinal plants with a potential to treat Alzheimer and associated symptoms. International Journal of Nutrition, Pharmacology, Neurological Diseases. 2012;2(2):84–91.
16. Rasmussen J, Langerman H. Alzheimer's disease–why we need early diagnosis. Degenerative neurological and neuromuscular disease. 2019;p. 123–130.
17. Sabbagh MN, Boada M, Borson S, Chilukuri M, Doraiswamy P, Dubois B, et al. Rationale for early diagnosis of mild cognitive impairment (MCI) supported by emerging digital technologies. The journal of prevention of Alzheimer's disease. 2020;7:158–164.
18. Custodio N, Montesinos R, Lira D, Herrera-Perez E, Chavez K, Hernandez-Córdova G, et al. Validation of the RUDAS in patients with a middle-level education in Lima, Peru. American Journal of Alzheimer's Disease & Other Dementias®. 2019;34(7-8):513–522.
19. Solomon PR, Brush M, Calvo V, Adams F, DeVeaux RD, Pendlebury WW, et al. Identifying dementia in the primary care practice. International psychogeriatrics. 2000;12(4):483–493.
20. Buschke H, Kuslansky G, Katz M, Stewart WF, Sliwinski MJ, Eckholdt HM, et al. Screening for dementia with the memory impairment screen. Neurology. 1999;52(2):231–231.
21. Tierney MC, Szalai JP, Dunn E, Geslani D, McDowell I. Prediction of probable Alzheimer disease in patients with symptoms suggestive of memory impairment: value of the Mini-Mental State Examination. Archives of family medicine. 2000;9(6):527.
22. Gifford DR, Cummings JL. Evaluating dementia screening tests: methodologic standards to rate their performance. AAN Enterprises 1999.
23. Custodio N, Herrera-Pérez E, Montesinos R, Lira D, Metcalf T. Brief cognitive tests validated in Peru for detection of cognitive impairment A systematic mapping of the scientific literature. Dementia & Neuropsychologia. 2020;14:134–144.
24. Peña-Casanova J, Blesa R, Aguilar M, Gramunt-Fombuena N, Gómez-Ansón B, Oliva R, et al. Spanish multicenter normative studies (NEURONORMA project): Methods and sample characteristics. Archives of Clinical Neuropsychology. 2009;24(4):307–319.
25. Espitia A, Duarte L. Neuronorma Colombia: aportes y características metodológicas. Neurología. 2021;.
26. Manos PJ, Wu R. The ten point clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients. The International Journal of Psychiatry in Medicine. 1994;24(3):229–244.
27. Custodio N, García A, Montesinos R, Lira D, Bendezú L. Validación de la prueba de dibujo del reloj-versión de Manos-como prueba de cribado para detectar demencia en una población adulta mayor de Lima, Perú. Revista Peruana de Medicina Experimental y Salud Pública. 2011;28:29–34.
28. Custodio N, Lira D, Montesinos R, Gleichgerrcht E, Manes F. Utilidad del Addenbrooke's Cognitive Examination versión en español en pacientes peruanos con enfermedad de Alzheimer y demencia frontotemporal. Vertex (Buenos Aires, Argentina). 2012;23(103):165–172.
29. Custodio N, Herrera-Perez E, Lira D, Roca M, Manes F, Báez S, et al. Evaluation of the INECO Frontal Screening and the Frontal Assessment Battery in Peruvian patients with Alzheimer's disease and behavioral variant Frontotemporal dementia. ENeurologicalSci. 2016;5:25–29.
30. Custodio N, Lira D, Herrera-Perez E, Nuñez del Prado L, Parodi J, Guevara-Silva E, et al. The memory alteration test discriminates between cognitively healthy status, mild cognitive impairment and Alzheimer's disease. Dementia and geriatric cognitive disorders extra. 2014;4(2):314–321.

31. Custodio N, Lira D, Herrera-Perez E, Montesinos R, Castro-Suarez S, Cuenca-Alfaro J, et al. Memory alteration test to detect amnestic mild cognitive impairment and early Alzheimer's dementia in population with low educational level. Frontiers in aging neuroscience. 2017;9:278.
32. Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. Journal of the American Geriatrics Society. 2005;53(4):695–699.
33. Katz MJ, Wang C, Nester CO, Derby CA, Zimmerman ME, Lipton RB, et al. T-MoCA: A valid phone screen for cognitive impairment in diverse community samples. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2021;13(1):e12144.
34. Pinto TC, Machado L, Bulgacov TM, Rodrigues-Júnior AL, Costa ML, Ximenes RC, et al. Is the Montreal Cognitive Assessment (MoCA) screening superior to the Mini-Mental State Examination (MMSE) in the detection of mild cognitive impairment (MCI) and Alzheimer's Disease (AD) in the elderly? International psychogeriatrics. 2019;31(4):491–504.
35. Loureiro C, Garcia C, Adana L, Yacelga T, Rodriguez-Lorenzana A, Maruta C. Use of the montreal cognitive assessment (MoCA) in Latin America: a systematic review. Revista de Neurologia. 2018;66(12):397–408.
36. INEI. 2023. Boletín de Análisis Demográfico N° 24 - Perú: Estimaciones y Proyecciones de la Población Nacional, por Año Calendario y Edad Simple. Instituto Nacional de Estadística e Informática.
37. INEI. 2021. Perú: Indicadores de Educación según Departamentos, 2011-2021. Instituto Nacional de Estadística e Informática.
38. Waldron-Perrine B, Axelrod BN. Determining an appropriate cutting score for indication of impairment on the Montreal Cognitive Assessment. International journal of geriatric psychiatry. 2012;27(11):1189–1194.
39. Bonferroni CE. Il calcolo delle assicurazioni su gruppi di teste. Studi in onore del professore salvatore ortu carboni. 1935;p. 13–60.
40. Dunn OJ. Multiple comparisons using rank sums. Technometrics. 1964;6(3):241–252.
41. Ivnik RJ, Malec JF, Smith GE, Tangalos EG, Petersen RC, Kokmen E, et al. Mayo's Older Americans Normative Studies: WAIS-R norms for ages 56 to 97. The Clinical Neuropsychologist. 1992;6(S1):1–30.
42. Ojeda N, Pino Rd, Ibarretxe-Bilbao N, Schretlen DJ, Peña J. Test de evaluación cognitiva de Montreal: normalización y estandarización de la prueba en población española. Rev neurol(Ed impr). 2016;p. 488–496.
43. McKinney W, et al. pandas: a foundational Python library for data analysis and statistics. Python for high performance and scientific computing. 2011;14(9):1–9.
44. Waskom ML. Seaborn: statistical data visualization. Journal of Open Source Software. 2021;6(60):3021.
45. Vallat R. Pingouin: statistics in Python. J Open Source Softw. 2018;3(31):1026.
46. Lee J, Burkett BJ, Min HK, Senjem ML, Lundt ES, Botha H, et al. Deep learning-based brain age prediction in normal aging and dementia. Nature Aging. 2022;2(5):412–424.
47. Sugden K, Caspi A, Elliott ML, Bourassa KJ, Chamarti K, Corcoran DL, et al. Association of pace of aging measured by blood-based DNA methylation with age-related cognitive impairment and dementia. Neurology. 2022;99(13):e1402–e1413.
48. Wu JW, Yaqub A, Ma Y, Koudstaal W, Hofman A, Ikram MA, et al. Biological age in healthy elderly predicts aging-related diseases including dementia. Scientific reports. 2021;11(1):15929.
49. Kingston A, Wohland P, Wittenberg R, Robinson L, Brayne C, Matthews FE, et al. Is late-life dependency increasing or not? A comparison of the Cognitive Function and Ageing Studies (CFAS). The lancet. 2017;390(10103):1676–1684.
50. Javaid H, Manor R, Kumarnsit E, Chatpun S. Decision tree in working memory task effectively characterizes EEG signals in healthy aging adults. IRBM. 2022;43(6):705–714.
51. Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging (albany NY). 2018;10(4):573.
52. Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. Journal of the international neuropsychological society. 2002;8(3):448–460.
53. Stern Y. Cognitive reserve. Neuropsychologia. 2009;47(10):2015–2028.
54. Clouston SA, Smith DM, Mukherjee S, Zhang Y, Hou W, Link BG, et al. Education and cognitive decline: an integrative analysis of global longitudinal studies of cognitive aging. The Journals of Gerontology: Series B. 2020;75(7):e151–e160.
55. Santos MP, Turner B, Chaparro MP. The double burden of malnutrition in Peru: an update with a focus on social inequities. The American Journal of Clinical Nutrition. 2021;113(4):865–873.
56. Gurvich C, Thomas N, Kulkarni J. Sex differences in cognition and aging and the influence of sex hormones. Handbook of clinical neurology. 2020;175:103–115.
57. Levine DA, Gross AL, Briceño EM, Tilton N, Giordani BJ, Sussman JB, et al. Sex differences in cognitive decline among US adults. JAMA network open. 2021;4(2):e210169–e210169.
58. Fine C, Jordan-Young R, Kaiser A, Rippon G. Plasticity, plasticity, plasticity… and the rigid problem of sex. Trends in cognitive sciences. 2013;17(11):550–551.
59. Gaete M, Jorquera S, Bello-Lepe S, Mendoza Y, Véliz M, Alonso-Sanchez M, et al. Resultados estandarizados del Montreal Cognitive Assessment (MoCA) para cribado neurocognitivo en población chilena. Neurología. 2023;38(4):246–255.
60. Ardila A, Ostrosky F. Guía para el diagnóstico neuropsicológico. editor no identificado; 2012.
61. Salthouse TA. When does age-related cognitive decline begin? Neurobiology of aging. 2009;30(4):507–514.
62. Kaur A, Edland SD, Peavy GM. The MoCA-Memory Index Score: an efficient alternative to paragraph recall for the detection of amnestic mild cognitive impairment. Alzheimer Disease & Associated Disorders. 2018;32(2):120–124.
63. Marcos G, Santabárbara J, Lopez-Anton R, De-la Cámara C, Gracia-García P, Lobo E, et al. Conversion to dementia in mild cognitive impairment diagnosed with DSM-5 criteria and with Petersen's criteria. Acta Psychiatrica Scandinavica. 2016;133(5):378–385.
64. Guerrero-Berroa E, Luo X, Schmeidler J, Rapp MA, Dahlman K, Grossman HT, et al. The MMSE orientation for time domain is a strong predictor of subsequent cognitive decline in the elderly. International journal of geriatric psychiatry. 2009;24(12):1429–1437.
65. Nucci M, Mapelli D, Mondini S. Cognitive Reserve Index questionnaire (CRIq): a new instrument for measuring cognitive reserve. Aging clinical and experimental research. 2012;24(3):218–226.
66. INEI. 2023. Producción y empleo informal en el Perú - Cuenta Satélite de la Economía Informal 2022. Instituto Nacional de Estadística e Informática.

67. Douaud G, Lee S, Alfaro-Almagro F, Arthofer C, Wang C, McCarthy P, et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604(7907):697–707.
68. Hampshire A, Azor A, Atchison C, Trender W, Hellyer PJ, Giunchiglia V, et al. Cognition and Memory after Covid-19 in a Large Community Sample. New England Journal of Medicine. 2024;390(9):806–818.
69. Holmes EA, O'Connor RC, Perry VH, Tracey I, Wessely S, Arseneault L, et al. Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. The lancet psychiatry. 2020;7(6):547–560.
70. Campodónico NM. El impacto del COVID-19 en el campo de la salud mental en América Latina y España: una revisión sistemática. Revista Calidad de vida y salud. 2022;p. 53–79.
71. da Silva Castanheira K, Sharp M, Otto AR. The impact of pandemic-related worry on cognitive functioning and risk-taking. PloS one. 2021;16(11):e0260061.